MicroRNA Childhood Cancer Catalog (M3Cs)

Publication Title	DOI	Year
MicroRNA-486-5p is an erythroid oncomiR of the myeloid leukemias of Down syndrome	https://doi.org/10.1182/blood-2014-06-581892	2015	Cell line 0 Master/Detail View	Cell line and drug 0 Master/Detail View	Clinical and drug 0 Master/Detail View	Clinical 3 Master/Detail View
MiR-10b regulates the proliferation and apoptosis of pediatric acute myeloid leukemia through targeting HOXD10	https://doi.org/10.26355/eurrev_201811_16275	2018	Cell line 0 Master/Detail View	Cell line and drug 0 Master/Detail View	Clinical and drug 0 Master/Detail View	Clinical 1 Master/Detail View
MicroRNA-183 promotes cell proliferation via regulating programmed cell death 6 in pediatric acute myeloid leukemia	https://doi.org/10.1007/s00432-016-2277-2	2017	Cell line 0 Master/Detail View	Cell line and drug 0 Master/Detail View	Clinical and drug 0 Master/Detail View	Clinical 2 Master/Detail View
Upregulation of microRNA-375 is associated with poor prognosis in pediatric acute myeloid leukemia	https://doi.org/10.1007/s11010-013-1754-z	2013	Cell line 0 Master/Detail View	Cell line and drug 0 Master/Detail View	Clinical and drug 0 Master/Detail View	Clinical 1 Master/Detail View
A three-miRNA-based expression signature at diagnosis can predict occurrence of relapse in children with t(8;21) RUNX1-RUNX1T1 acute myeloid leukaemia	https://doi.org/10.1111/bjh.14950	2018	Cell line 0 Master/Detail View	Cell line and drug 0 Master/Detail View	Clinical and drug 0 Master/Detail View	Clinical 3 Master/Detail View
Upregulation of microRNA-125b contributes to leukemogenesis and increases drug resistance in pediatric acute promyelocytic leukemia	https://doi.org/10.1186/1476-4598-10-108	2011	Cell line 0 Master/Detail View	Cell line and drug 0 Master/Detail View	Clinical and drug 0 Master/Detail View	Clinical 2 Master/Detail View
MicroRNA patterns associated with clinical prognostic parameters and CNS relapse prediction in pediatric acute leukemia	https://doi.org/10.1371/journal.pone.0007826	2009	Cell line 0 Master/Detail View	Cell line and drug 0 Master/Detail View	Clinical and drug 0 Master/Detail View	Clinical 11 Master/Detail View
Aberrant expression and mechanism of miR-130b-3p/phosphatase and tensin homolog in nephroblastoma in children	https://doi.org/10.3892/etm.2019.7643	2019	Cell line 0 Master/Detail View	Cell line and drug 0 Master/Detail View	Clinical and drug 0 Master/Detail View	Clinical 1 Master/Detail View
Effects of MicroRNA-19b on the Proliferation, Apoptosis, and Migration of Wilms' Tumor Cells Via the PTEN/PI3K/AKT Signaling Pathway	https://doi.org/10.1002/jcb.25999	2017	Cell line 0 Master/Detail View	Cell line and drug 0 Master/Detail View	Clinical and drug 0 Master/Detail View	Clinical 1 Master/Detail View
Circulating serum miRNAs as potential biomarkers for nephroblastoma	https://doi.org/10.1002/pbc.25481	2015	Cell line 0 Master/Detail View	Cell line and drug 0 Master/Detail View	Clinical and drug 0 Master/Detail View	Clinical 2 Master/Detail View
MicroRNA-197 Mediates the Overgrowth and Anti-Apoptotic Effects by Downregulating Insulin-Like Growth Factor-Binding Protein-3 During Nephroblastoma Tumorigenesis.	https://doi.org/10.1080/15513815.2016.1178360	2016	Cell line 0 Master/Detail View	Cell line and drug 0 Master/Detail View	Clinical and drug 0 Master/Detail View	Clinical 1 Master/Detail View
miRNA profiles as a predictor of chemoresponsiveness in Wilms' tumor blastema.	https://doi.org/10.1371/journal.pone.0053417	2013	Cell line 0 Master/Detail View	Cell line and drug 0 Master/Detail View	Clinical and drug 0 Master/Detail View	Clinical 7 Master/Detail View
The IGF2 intronic miR-483 selectively enhances transcription from IGF2 fetal promoters and enhances tumorigenesis	https://doi.org/10.1101/gad.224170.113	2013	Cell line 0 Master/Detail View	Cell line and drug 0 Master/Detail View	Clinical and drug 0 Master/Detail View	Clinical 2 Master/Detail View
Aberrant Expression of Some Circulating miRNAs in Childhood Acute Lymphoblastic Leukemia "	https://doi.org/10.1007/s10528-018-9844-y	2018	Cell line 0 Master/Detail View	Cell line and drug 0 Master/Detail View	Clinical and drug 0 Master/Detail View	Clinical 2 Master/Detail View
Circulating microRNAs as minimal residual disease biomarkers in childhood acute lymphoblastic leukemia.	https://doi.org/10.1186/s12967-019-2114-x	2019	Cell line 0 Master/Detail View	Cell line and drug 0 Master/Detail View	Clinical and drug 0 Master/Detail View	Clinical 4 Master/Detail View
Clinical impact of circulating microRNAs as blood-based marker in childhood acute lymphoblastic leukemia.	https://doi.org/10.1007/s13277-016-4948-7	2016	Cell line 0 Master/Detail View	Cell line and drug 0 Master/Detail View	Clinical and drug 0 Master/Detail View	Clinical 3 Master/Detail View
Clinical utility of miR-143/miR-182 levels in prognosis and risk stratification specificity of BFM-treated childhood acute lymphoblastic leukemia	https://doi.org/10.1007/s00277-018-3292-y	2018	Cell line 0 Master/Detail View	Cell line and drug 0 Master/Detail View	Clinical and drug 0 Master/Detail View	Clinical 2 Master/Detail View
Combining miRNA and mRNA Expression Profiles in Wilms Tumor Subtypes	https://doi.org/10.3390/ijms17040475	2016	Cell line 0 Master/Detail View	Cell line and drug 0 Master/Detail View	Clinical and drug 0 Master/Detail View	Clinical 4 Master/Detail View
Competitive endogenous RNA (ceRNA) regulation network of lncRNAs, miRNAs, and mRNAs in Wilms tumour	https://doi.org/10.1186/s12920-019-0644-y	2019	Cell line 0 Master/Detail View	Cell line and drug 0 Master/Detail View	Clinical and drug 0 Master/Detail View	Clinical 1 Master/Detail View
A Children's Oncology Group and TARGET initiative exploring the genetic landscape of Wilms tumor	https://doi.org/10.1038/ng.3940	2017	Cell line 0 Master/Detail View	Cell line and drug 0 Master/Detail View	Clinical and drug 0 Master/Detail View	Clinical 2 Master/Detail View

Publications